Table 3.

Multivariable Subgroup Analysis of Overall Survival for the No CTX and CTX Cohorts

Variable	Hazard Ratio (95% CI)	P*
Chemotherapy use
Yes	1.19 (1.01 – 1.39)	0.039
No	―	―
Age at diagnosis, median	1.06 (1.06 – 1.06)	< 0.001
Race, No. (%)
White	―	―
Black	1.41 (1.35 – 1.47)	< 0.001
Others/Unknown	0.78 (0.72 – 0.84)	< 0.001
Charlson-Deyo Score, No. (%)
0	―	―
1	1.59 (1.54 – 1.65)	< 0.001
2+	2.59 (2.41 – 2.77)	< 0.001
Facility Type, No. (%)
Non-Academic/Research Program	―	―
Academic/Research Program	0.87 (0.84 – 0.90)	< 0.001
Year of Diagnosis, No. (%)
≥ 2004 – ≤ 2007	―	―
> 2007 – ≤ 2009	1.05 (1.01 – 1.09)	0.023
> 2009 – ≤ 2011	1.05 (0.99 – 1.10)	0.082
> 2011 – ≤ 2013	1.08 (1.00 – 1.16)	0.050
AJCC clinical T stage, No. (%)
1	―	―
2	1.11 (1.08 – 1.15)	< 0.001
3	1.30 (1.22 – 1.39)	< 0.001
4	1.52 (1.19 – 1.93)	< 0.001
Unknown	1.12 (1.07 – 1.18)	< 0.001
AJCC clinical N stage, No. (%)
0	―	―
1	1.22 (1.03 – 1.42)	0.018
Unknown	0.99 (0.95 – 1.04)	0.739
AJCC pathologic T stage, No. (%)
1–2	―	―
3	1.35 (1.31 – 1.40)	< 0.001
4	2.07 (1.86 – 2.31)	< 0.001
Unknown	1.16 (1.07 – 1.25)	< 0.001
AJCC pathologic N stage, No. (%)
0	―	―
1	1.55 (1.45 – 1.66)	< 0.001
Unknown	0.97 (0.93 – 1.01)	0.101
Gleason Score, No. (%)
2–7	―	―
8–10	1.65 (1.60 – 1.71)	< 0.001
Unknown	1.23 (1.12 – 1.35)	< 0.001
PSA, No. (%)
< 10	0.82 (0.78 – 0.85)	< 0.001
≤ 10– < 20	―	―
≥ 20	0.97 (0.92 – 1.03)	0.381
Unknown	0.94 (0.89 – 0.99)	0.028
Surgical Margin, No. (%)
Negative	―	―
Positive	1.15 (1.12 – 1.19)	< 0.001
Unknown	0.93 (0.82 – 1.06)	0.277

Abbreviations: CTX, Chemotherapy; CI, Confidence interval; AJCC, American Joint Committee on Cancer; PSA, Prostate-specific antigen; ADT, Androgen deprivation therapy

^*Bolded P Values are significant